...
首页> 外文期刊>Pharmacoepidemiology and drug safety >Patterns of asthma medication use: early asthma therapy initiation and asthma outcomes at age 8.
【24h】

Patterns of asthma medication use: early asthma therapy initiation and asthma outcomes at age 8.

机译:哮喘药物使用的模式:早期哮喘治疗的开始和8岁时哮喘的预后。

获取原文
获取原文并翻译 | 示例

摘要

Wheeze has many underlying pathophysiologies in childhood, but is the main reason for anti-asthma drugs prescription. This study was conducted to describe asthma medication use patterns among children in their first eight years of life. Longitudinal medication use data from 777 children participating in the PIAMA study were used. Medication patterns were described for four groups that started therapy before the third birthday, when the peak in prescriptions occurred in our cohort; short-acting beta-agonists (SABA), inhaled corticosteroids (ICS), SABA + ICS or none of these. One third (n = 255) of the children received a first SABA or ICS prescription before age 8. Only three children (1.2%) used medication continuously during follow-up. Of the children who started SABA, 53.8% discontinued within 1-2 years. Of the children who started ICS before age 3, 42.1% discontinued within 1-2 years and 31.6% received additional SABA. 41.5% of the children who started SABA + ICS used this short-term (/= 3 years). Fifteen percent of children who did not start asthma therapy in their first 3 years of life did receive prescriptions between age 3 and 8. Children prescribed SABA + ICS before age 3 had the highest prevalence of hyper responsiveness at age 8, and similar prevalence of atopy as the other groups. Asthma medication is prescribed frequently in the first 8 years of life, particularly before age 3, and only few children use it continuously. ICS and SABA prescription occurs especially in those who were more likely to develop signs of asthma at age 8.
机译:喘息在儿童时期有许多潜在的病理生理学,但是服用抗哮喘药的主要原因。这项研究的目的是描述儿童在生命的头八年中使用哮喘药物的方式。使用来自参与PIAMA研究的777名儿童的纵向药物使用数据。描述了四组在三岁生日之前开始治疗的药物模式,当时我们的队列中出现了处方高峰。短效β受体激动剂(SABA),吸入性糖皮质激素(ICS),SABA + ICS或全都不使用。三分之一(n = 255)的儿童在8岁之前接受了第一批SABA或ICS处方。只有三名儿童(1.2%)在随访期间不断使用药物。开始使用SABA的儿童中,有53.8%在1-2年内停药。在3岁之前开始接受ICS的儿童中,有42.1%在1-2年内终止接受治疗,有31.6%的儿童接受了额外的SABA。开始使用SABA + ICS的儿童中有41.5%的儿童是在短期内( / = 3岁)。在生命的前3年中未开始哮喘治疗的儿童中,有15%的儿童在3至8岁之间接受过处方。3岁之前开具SABA + ICS的儿童在8岁时过敏反应的患病率最高,并且特应性患病率也相似和其他群体一样。在生命的头8年内(尤其是在3岁之前)经常开处方哮喘药,只有很少的孩子连续使用它。 ICS和SABA处方特别是在那些更可能在8岁时出现哮喘症状的患者中发生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号